TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
Transcenta, Biologics, Antibody, Claudin 18.2
News & Events
Discover Future Talk - an English language podcast series in which curious minds from diverse fields come together to discuss their personal visions for the future of Science and Technology.
- Integrate HiCB and novel facility design to provide flexibility, speed, high quality at low cost - Platform designed to simplified PD while minimizing tech transfer, scale up and manufacturing risks - Showcase implementation strategy and plan
At a recent Evaluating BioPharma virtual event, moderator John Bonham-Carter asked Chris Hwang, chief technology officer at Transcenta Holding Ltd., about Chris’ journey and experiences with continuous bioprocessing thus far in his career.
The safety and tolerability of TST001 is under investigation as a potential treatment option for patients with gastric/gastroesophageal junction cancer and other locally advanced or metastatic solid tumors as part of a phase 1 trial.
As downstream bioprocessing improvements continue, efforts are underway to integrate downstream processes into continuous operations.